Skip to main content

How long will I need to take Kisunla?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on Aug 14, 2025.

Official Answer by Drugs.com

The length of treatment with Kisunla (donanemab-azbt) for Alzheimer's disease is different for each person, but usually lasts until amyloid plaques are cleared. According to the manufacturer, the optimum duration of treatment should be informed by clinical judgement based on brain scans.

The recommended dosing schedule is as follows:

Infusion Number Dose Week Administration Time
Infusion 1 350 mg 1 Administered over ~30 minutes
Infusion 2 700 mg 5 Administered over ~30 minutes
Infusion 3 1,050 mg 9 Administered over ~30 minutes
Infusion 4 and beyond 1,400 mg 13 and every 4 weeks thereafter Administered over ~30 minutes

Your healthcare provider will monitor how well the medication is working through PET scans of your brain. Once they see Kisunla has reduced amyloid plaques to low levels, they may consider stopping the medication.

In clinical trials, 69% of people taking Kisunla had amyloid levels low enough to stop treatment. Keep in mind that after stopping Kisunla it is possible for amyloid levels to go back up. Research is ongoing to determine whether additional doses of Kisunla might be needed if this happens.

This is not all the information you need to know about Kisunla (donanemab-azbt) for safe and effective use. Review the full Kisunla (donanemab-azbt) information, and discuss this and any questions you have with your doctor or other health care provider.

References
  1. Eli Lilly and Company. (2025, July 14). What is the optimum duration of treatment with Kisunla™ (donanemab-azbt)? Eli Lilly and Company. Retrieved from https://medical.lilly.com/us/products/answers/what-is-the-optimum-duration-of-treatment-with-kisunla-donanemab-azbt-219812
  2. Kisunla [package insert]. Updated July 2025. Eli Lilly and Company. Accessed September 11, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=190352d4-ef62-4679-b4fa-e846e2766afa

Read next

How do I decide between Leqembi and Kisunla?

Leqembi (lecanemab-irmb) and Kisunla (donanemab-azbt) are two injectable treatments for Alzheimer’s disease. While both medications work by reducing amyloid plaques in the brain, there are some differences to consider when deciding between the two. These include effectiveness, side effects, and cost.

Continue reading

Will insurance cover Kisunla treatment?

Kisunla treatment typically requires a prior authorization approval from your commercial insurance company before they will pay for it. Medicare Part B may pay for Kisunla and brain imaging scans if you are eligible, but you must first meet your yearly deductible and then pay coinsurance costs, which are usually 20%. Continue reading

How well does Kisunla work?

In studies, treatment with Kisunla significantly slowed Alzheimer's disease clinical decline when compared to a group who received a placebo. People with the least advanced disease experienced the strongest outcomes, with a 35% slowing of decline on the iADRS score, which measures memory, thinking, and daily functioning. Continue reading

See also:

Related medical questions

Drug information

Related support groups